Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2010-05-17 M&A Activity
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
PHARMING INITIATES DIVESTMENT OF DNAGE
M&A Activity Classification · 99% confidence The document is a press release dated May 17, 2010, announcing that Pharming Group NV has initiated the process to divest part of its interest in its subsidiary DNage BV. This action involves settling earn-out payments via share issuance and retaining a partial interest (51% initially). It also mentions the resignation of a board member (Dr. Rein Strijker) to become CEO of DNage and the ongoing recruitment of a CFO. The core subject is a significant corporate restructuring/transaction involving asset divestment and management changes, which directly relates to capital structure and financing activities. While management changes are mentioned, the primary driver and focus is the financial transaction (divestment/spin-off) to reduce cash needs and refocus resources. This aligns best with the 'Capital/Financing Update' (CAP) category, as it details a change in capital structure and financing strategy, rather than being a formal M&A announcement (TAR) or a simple management change announcement (MANG). It is not a formal regulatory filing like a 10-K or an ER, but a strategic corporate action announcement.
2010-05-17 English
Pharming provides update on outstanding shares
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Pharming Group NV titled "PHARMING PROVIDES UPDATE ON OUTSTANDING SHARES." It explicitly details the issuance of 6,256,028 ordinary shares due to the conversion of private bonds, resulting in a new total of 162,921,104 outstanding shares. This action directly relates to a change in the company's capital structure (issuance of shares related to debt conversion). This fits the definition of 'Share Issue/Capital Change' (SHA) more precisely than a general financing update (CAP) or a transaction in own shares (POS), as it is a direct consequence of a financing instrument conversion leading to equity issuance.
2010-05-17 English
Annual Report 2009
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2009' and contains comprehensive sections including a letter from the CEO, management reports, consolidated financial statements, notes to the financial statements, and an auditor's report. It covers the full fiscal year 2009 and provides detailed financial and operational performance data, fitting the definition of an Annual Report (10-K). FY 2009
2010-04-30 English
Pharming publishes first quarter 2010 financial report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first quarter ended March 31, 2010. It contains detailed financial statements, including the Consolidated Statement of Financial Position and the Consolidated Statement of Income, along with management's analysis of the financial results. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2010
2010-04-22 English
Interim / Quarterly Report 2010
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first quarter ended March 31, 2010. It contains detailed financial statements, including the Consolidated Statement of Financial Position and the Consolidated Statement of Income, along with management's analysis of the financial results. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2010
2010-04-22 English
Swedish Orphan Biovitrum and Pharming sign Rhucin® distribution agreement
Regulatory Filings Classification · 95% confidence The document is a press release dated April 15, 2010, announcing an exclusive 10-year distribution agreement between Swedish Orphan Biovitrum and Pharming Group NV regarding the drug Rhucin®. It details the terms of the agreement, background on the drug and the disease (Hereditary Angioedema), and company information. This type of announcement, which details a significant business transaction (distribution agreement, potential milestones, royalties) but is not a formal regulatory filing like a 10-K, ER, or IR, fits best under the general category of corporate news or a specific business update. Since there is no specific category for 'Distribution Agreement Announcement', and it is not a management change (MANG), financing event (CAP), or M&A (TAR), it falls under the general regulatory/corporate announcement category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard corporate news releases that are not explicitly covered by other codes.
2010-04-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.